Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential.
about
SNAP-23 and VAMP-3 contribute to the release of IL-6 and TNFα from a human synovial sarcoma cell lineCurrent advances in orthodontic painCurrent status and future directions of botulinum neurotoxins for targeting pain processingBotulinum Toxin Type a as a Therapeutic Agent against Headache and Related DisordersOnabotulinumtoxinA for trigeminal neuralgia: a review of the available dataTNFα induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion.Botulinum Toxin as a Pain Killer: Players and Actions in AntinociceptionCGRP inhibits neurons of the bed nucleus of the stria terminalis: implications for the regulation of fear and anxiety.Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up.Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction.Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK-CREB cascade: a potential mechanism of inflammatory pain.Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy.Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial.Epoxyeicosatrienoic acids are endogenous regulators of vasoactive neuropeptide release from trigeminal ganglion neuronsTherapeutic use of botulinum toxin in migraine: mechanisms of action.A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.αCGRP is essential for algesic exocytotic mobilization of TRPV1 channels in peptidergic nociceptors.OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patientsTowards new uses of botulinum toxin as a novel therapeutic toolCargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons.Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents.Insights into the mechanism of onabotulinumtoxinA in chronic migraine.Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A.Endogenous BDNF augments NMDA receptor phosphorylation in the spinal cord via PLCγ, PKC, and PI3K/Akt pathways during colitisNociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous ImmunityBotulinum toxin type A induces changes in the chemical coding of substance P-immunoreactive dorsal root ganglia sensory neurons supplying the porcine urinary bladderThe effects of intra-articular resiniferatoxin on monosodium iodoacetate-induced osteoarthritic pain in rats.Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients.Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.Endogenous PI3K/Akt and NMDAR act independently in the regulation of CREB activity in lumbosacral spinal cord in cystitis.Treatment of refractory pain with botulinum toxins--an evidence-based review.Targeted secretion inhibitors-innovative protein therapeuticsBotulinum neurotoxin for pain management: insights from animal models.CGRP and NO in the trigeminal system: mechanisms and role in headache generation.Transient receptor potentials (TRPs) and anaphylaxis.Botulinum toxin for neuropathic pain and spasticity: an overview.Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulation in the gut mucosa.
P2860
Q24316444-46A8FF46-150F-4086-9D31-A4D19CEA6ED8Q26747178-A4B0A6F0-3138-49BE-A91D-A343FCCAC3C1Q26778129-CBD9A0BE-06DF-488B-AFBB-3ADB0023F002Q26781281-6152A97D-1548-486F-9C5D-65F86ED01B4EQ26796286-E2A426D8-ECFB-4FF1-A1FB-0CA7EC268E73Q27348801-C0E30130-EE5E-42B9-A288-0522885D3C5BQ28084583-BEA6C09B-082F-4E0E-A0B4-410FF32959F0Q30435769-373172DB-ED09-488E-87E9-A3E1192AB6E0Q33828749-5532A841-40FD-468F-8E5F-EA155E7AE8A3Q33915263-9A156D57-71DE-45B3-B5B9-9F4C5CCBC1DAQ33957870-7615D840-AA94-4991-87CB-2EA0CF678C88Q34029307-3D887979-5301-4161-8EE6-E65E687FB6D9Q34125262-FF6B4D4B-3CC1-458B-A5E8-903DA30AC19AQ34255178-5050F53C-FA1C-423C-AFA5-5E5EF5F1A9D7Q34326148-583A83BC-F8B8-4B86-80C0-F4FAE81D1CB3Q34376228-87A5AACA-7916-4612-9278-10956B771CA8Q34419654-D2DD1396-1445-46AC-B829-7AA55AFB5E5EQ34675649-9CEE9D7C-F795-4BCE-ACD1-1694767C99E5Q34793162-D599A812-4602-4C6E-A418-B7159A72E407Q35266832-63A8D21C-3EDE-4154-8D05-EF53FD365AA1Q35534477-15434FD4-F26E-42AC-A776-3FA8C7CCBCFFQ35542237-62FBA691-6ED4-4897-88DC-207C9D6AE87AQ35548169-EB2FAE91-ED1B-4C6F-916E-FBC9CE20A77BQ35691221-6719B583-3DFD-4CC2-82B8-D00407EF1BECQ35837340-2CD49AFC-0316-44C4-9B1E-3960849FE47AQ35888886-4B018CA7-8567-4C93-B890-2AA8E8316330Q35986155-590E8C59-15CC-4470-ACCE-3FF22E6ADFA4Q36165375-5746E613-170E-4843-A455-EF08A1FE3CB6Q36329632-752708D9-C573-496B-8366-B20C1406F3CBQ36488665-D1DAA740-A999-4B52-8BEF-1AE28CCEE022Q36507209-3E7945C3-04BA-4F6B-AB2D-A71718564495Q36518248-761FDBBC-6158-46E7-B6E6-F0B054444856Q37425758-11EAA76F-B87B-4DD9-814A-02F41EE4BBEDQ37940623-0AACB019-CF38-4315-86C8-6C13714101CCQ37954277-8806E5A8-5B44-4BAF-ACBA-954ED8D7B93AQ37954278-96A98BC0-2358-4884-B0F2-18FAA9E700B3Q38025661-95009F04-814F-4332-A253-61B43F7F5EC3Q38042845-63CC3C7F-6562-4A57-BE88-8E5A3A2196EAQ38196928-D6F73D82-BBED-4A7F-A9EE-91B0686D76DDQ38245673-3A2225A9-1A24-451B-8479-F18627CFF745
P2860
Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Activation of TRPV1 mediates c ...... th anti-nociceptive potential.
@en
Activation of TRPV1 mediates c ...... th anti-nociceptive potential.
@nl
type
label
Activation of TRPV1 mediates c ...... th anti-nociceptive potential.
@en
Activation of TRPV1 mediates c ...... th anti-nociceptive potential.
@nl
prefLabel
Activation of TRPV1 mediates c ...... th anti-nociceptive potential.
@en
Activation of TRPV1 mediates c ...... th anti-nociceptive potential.
@nl
P2093
P50
P1476
Activation of TRPV1 mediates c ...... th anti-nociceptive potential.
@en
P2093
Gary W Lawrence
J Oliver Dolly
Jianghui Meng
K Roger Aoki
Saak V Ovsepian
P304
P356
10.1523/JNEUROSCI.5490-08.2009
P407
P577
2009-04-01T00:00:00Z